Treatment results of children with the diagnosis of acute myeloid leukemia. Is trisomy 21 an important cause of mortality?
DOI:
https://doi.org/10.18203/2349-3291.ijcp20231136Keywords:
AML, Down syndrome, HSCT, FLT3-ITDAbstract
Background: Acute myeloid leukemia (AML) is the second most common leukemia accounts for 20% of childhood leukemia. Intensive chemotherapy and hematopoietic stem cell transplantation (HSCT) improve outcomes. In this study, it was aimed to present the clinical features and treatment results of patients diagnosed with pediatric AML in the last three years.
Methods: It is an observational clinical study, patients who received chemotherapy and HSCT with the diagnosis of AML between 2018 and 2020 were retrospectively evaluated. Age, gender, AML subtype, genetic characteristics, laboratory findings, treatment responses, febrile neutropenia and fungal infection frequencies of the patients were evaluated. HSCT indications, pre-transplant bone marrow aspiration results, transplant type, donor characteristics, and post-transplant complications of patients who underwent HSCT were recorded. Post-treatment status and treatment success rates of the patients were evaluated.
Results: Of the 46 patients included in the study, 26 were female and 20 were male. The mean age was 8.2 ± 5.75 years. The most common subtypes were AML M4 and M5 with 9 patients. Total of 201 febrile neutropenia attacks were observed. Suspicious or definite proven Aspergillus infection was detected in 20 of the patients. HSCT was applied to 27 of the patients. Four patients were Down syndrome-myeloid leukemia (DS-ML) and FLT3-ITD mutation was detecetd in 5 patients.
Conclusions: FLT3-ITD mutation, relapse disease, and pre-HSCT M2 bone marrow were found to be highly correlated with progressive disease and mortality. In addition, patients with Down syndrome had a high mortality due to additional comorbidity and drug adverse effects.
References
Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S. Committee, C.O.G.A.M.L. Children’s oncology group’s 2013 blueprint for research: Acute myeloid leukemia. Pediatr Cancer. 2013;60:964-71.
Rubnitz JE. Current management of childhood acute myeloid leukemia. Paediatr Drugs. 2017;19:1-10.
Creutzig U, Zimmermann M, Reinhardt D, Rasche M, von Neuhoff C, Alpermann T, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122:3821-30.
Song TY, Lee SH, Kim G, Baek HJ, Hwang TJ, Kook H. Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia. Blood Res 2018;53:25-34.
Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk strafication, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):51-65.
Taga T, Tomizawa D, Takahashi H, Adachi S. Acute myeloid leukemia in children: Current status and future directions. Pediatr Int. 2016:58;71-80.
Iland H.J, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: A non-randomised phase 2 trial. Lancet Haematol. 2015;2:357-66.
Rajpurkar M, Alonzo TA, Wang YC, Gerbing RB, Gamis AS, Feusner JH et al. Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631. J Pediatr Hematol Oncol. 2019;41:51-5.
De Azevedo AC, Matsuda E, Cervellini JY, Prandi LR, Omae C, Jotta PY et al. Early Mortality in Children and Adolescents with Acute Promyelocytic Leukemia: Experience of the Boldrini Children's Center. J Pediatr Hematol Oncol. 2020;42(7):641-6.
Zhang Y, Wang L, Zhang R, Qi P, Xie J, Shi H et al. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005). Pediatr Hematol Oncol. 2019;36:399-409.
Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019;187:157-62.
Jin B, Zhang Y, Hou W, Cao F, Lu M, Yang H et al. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide. J Cancer Res Clin Oncol. 2020;146(2):485-92.
Linabery AM, Arico M, Basso G, Olshan AF, Heerema NA, Ross JA. Congenital abnormalities and acute leukemia among children with Down syndrome: a Children’s Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2572-7.
Ross JA, Spector LG, Robinson LL, Olshan AF. Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer 2005;44(1):8-12.
Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118(22):5905-13.
Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-61.
Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009;15(13):4263-9.
Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108(7):2358-65.
Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 2011;29(24):3293-300.
